Abstract:KLF4 plays an important role in orchestrating a variety of cellular events, including cell-fate decision, genome stability and apoptosis. Its deregulation is correlated with human diseases such as breast cancer and gastrointestinal cancer. Results from recent biochemical studies have revealed that KLF4 is tightly regulated by posttranslational modifications. Here we report a new finding that KLF4 orchestrates estrogen receptor signaling and facilitates endocrine resistance. We also uncovered the underlying mechanism that alteration of KLF4 by posttranslational modifications such as phosphorylation and ubiquitylation changes tumor cell response to endocrine therapy drugs. IHC analyses using based on human breast cancer specimens showed the accumulation of KLF4 protein in ER-positive breast cancer tissues. Elevated KLF4 expression significantly correlated with prognosis and endocrine resistance. Our drug screening for suppressing KLF4 protein expression led to identification of Src kinase to be a critical player in modulating KLF4-mediated tamoxifen resistance. Depletion of VHL (von Hippel-Lindau tumor suppressor), a ubiquitin E3 ligase for KLF4, reduces tumor cell sensitivity to tamoxifen. We demonstrated phosphorylation of VHL by Src enhances proteolysis of VHL that in turn leads to upregulation of KLF4 and increases endocrine resistance. Suppression of Src-VHL-KLF4 cascade by Src inhibitor or enhancement of VHL-KLF4 ubiquitination by TAT-KLF4 (371-420AAa) peptides re-sensitizes tamoxifen-resistant breast cancer cells to tamoxifen treatment. Taken together, our findings demonstrate a novel role for KLF4 in modulating endocrine resistance via the Src-VHL-KLF4 axis.

Interplay between arginine methylation and ubiquitylation regulates KLF4-mediated genome stability and carcinogenesis

Arginine Methylation of Hnrnp K Enhances P53 Transcriptional Activity.

H3K4 Methyltransferase Activity Is Required for MLL4 Protein Stability

New Insight into the Significance of KLF4 PARylation in Genome Stability, Carcinogenesis, and Therapy.

LARP7 is a BRCA1 Ubiquitinase Substrate and Regulates Genome Stability and Tumorigenesis

Arginine methyltransferase PRMT5 methylates and stabilizes KLF5 via decreasing its phosphorylation and ubiquitination to promote basal-like breast cancer

The cross-talk between methylation and phosphorylation in lymphoid-specific helicase drives cancer stem-like properties

Novel Insight into KLF4 Proteolytic Regulation in Estrogen Receptor Signaling and Breast Carcinogenesis

Functional Analysis of the Roles of Posttranslational Modifications at the P53 C Terminus in Regulating P53 Stability and Activity

Role For Kruppel-Like Factor 4 In Determining The Outcome Of P53 Response To Dna Damage

Regulation of KLF4 by Posttranslational Modification Circuitry in Endocrine Resistance.

Epigenetic Inactivation of KLF4 is Associated with Urothelial Cancer Progression and Early Recurrence

DNA methylation modifier LSH inhibits p53 ubiquitination and transactivates p53 to promote lipid metabolism

Data from Role for Krüppel-Like Factor 4 in Determining the Outcome of P53 Response to DNA Damage

3090 – KDM4A/C SUSTAIN AN ONCOGENIC PROGRAM BY EPIGENETIC REWIRING OF ONCOGENIC AND LINEAGE ENHANCERS

Methylated DNMT1 and E2F1 Are Targeted for Proteolysis by L3MBTL3 and CRL4DCAF5 Ubiquitin Ligase

Dysregulation of arginine methylation in tumorigenesis

KLF4 transcription factor in tumorigenesis

PRMT5 activates KLF5 by methylation to facilitate lung cancer

Non-canonical MLL1 activity regulates centromeric phase separation and genome stability

Klf4 Glutamylation is Required for Cell Reprogramming and Early Embryonic Development in Mice.